Ratings Enanta Pharmaceuticals, Inc.

Equities

ENTA

US29251M1062

Market Closed - Nasdaq Other stock markets 21:00:01 02/05/2024 BST			5-day change	1st Jan Change
13.94 ^USD	+2.80%		+11.70%	+48.14%

04-30	Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer	CI
02-09	Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ENANTA PHARMACEUTICALS, INC.	+48.14%	294M	C+
MODERNA, INC.	+26.28%	48.09B	B-
IQVIA HOLDINGS INC.	-3.99%	40.43B	B
LONZA GROUP AG	+46.68%	40.62B	A
CELLTRION, INC.	-6.20%	28.36B	C
ICON PUBLIC LIMITED COMPANY	+6.36%	24.89B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.47%	19.01B	B
MEDPACE HOLDINGS, INC.	+27.58%	12.09B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.75%	11.8B	C+
BIO-TECHNE CORPORATION	-2.02%	11.88B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes